MedPath

Interest of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Auditory Hallucinations

Phase 2
Completed
Conditions
Schizophrenic Disorders
Registration Number
NCT02525315
Lead Sponsor
University Hospital, Caen
Brief Summary

Auditory hallucinations are common (present in 60-70% of cases) and extremely debilitating. Behavioral disorders associated with them can have serious social repercussions. However, in 25% of cases the usual antipsychotic drug treatments are incompletely or totally ineffective.

Fifteen subjects will be included after collection and signed their informed consent.

The rTMS treatment is made of 4 sessions of 13 minutes spread over two days, at a frequency of 20 Hz and an intensity of 80% of motor threshold at rest. These constants are used to stay below the risk of occurrence of seizures, the only serious side effects identified. Furthermore the rTMS treatment is almost painless: tension headaches are the main side effects and make amends with simple analgesics. rTMS is devoid of neurocognitive effects. The LEFT stimulation site will be established through a anatomofunctional imaging before treatment (between D-7 and D0).

Treatment efficacy will be evaluated daily during treatment (days 1 and 2) and during the first 2 weeks of starting treatment.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
15
Inclusion Criteria
  • Patients with schizophrenic disorders aged from 18 to 60 years old
  • Patients suffering from auditory hallucinations undergoing antipsychotic treatments
  • Written signed consent
Exclusion Criteria
  • Pregnancy or breastfeeding
  • Counter-indication to MRI or to rTMS

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
HOFFMAN scorechange between baseline and day 3 or day 12
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Caen University Hospital

🇫🇷

Caen, France

© Copyright 2025. All Rights Reserved by MedPath